Anti-Mouse CD8 (Clone YTS 169) - Purified in vivo GOLD™ Functional Grade

Leinco Technologies
Product Code: LEI-C2442
Product Group: Primary Antibodies
CodeSizePrice
LEI-C2442-1.0mg1.0 mg£175.00
Quantity:
LEI-C2442-5.0mg5.0 mg£380.00
Quantity:
LEI-C2442-25mg25 mg£1,014.00
Quantity:
LEI-C2442-50mg50 mg£1,556.00
Quantity:
LEI-C2442-100mg100 mg£2,159.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Host Type: Rat
Antibody Isotype: IgG2b κ
Antibody Clonality: Monoclonal
Antibody Clone: YTS-169
Regulatory Status: RUO
Target Species: Mouse
Applications:
  • Depletion
  • Flow Cytometry
  • Immunohistochemistry- Frozen Section (IHC-F)
  • In Vivo Assay
  • Western Blot (WB)
Shipping:
2-8°C
Storage:
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Further Information

Antigen Distribution:
CD8 is expressed on blood lymphocytes, a subset of NK cells, and thymocytes. Persons with HIV exhibit increased levels of CD8+ lymphocytes.
Concentration:
? 5.0 mg/ml
Conjugate/Tag/Label:
in vivo GOLD™, Purified in vivo Functional Grade
Format:
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Formulation:
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Immunogen:
CBA mouse thymocytes
Long Description:
CD8 is made up of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8 is part of the Ig superfamily that expresses primarily as CD8a homodimers. CD8a is a 32-34 kD type I glycoprotein that can also form heterodimers with CD8b. CD8 is an antigen co-receptor on T cells that mediates efficient cell to cell interactions within the immune system. CD8 coupled with the T cell receptor on the T lymphocyte recognizes an antigen displayed by an antigen presenting cell (APC) in the context of class I MHC molecules. The CD8 co-receptor also plays a role in T cell signaling by interacting with Lck (lymphocyte-specific protein tyrosine kinase) which leads to the activation of transcription factors that affect the expression of certain genes.
Purity:
?95% monomer by analytical SEC, >95% by SDS Page
Target:
CD8

References

1. Parnes, J. R. et al. (1989) Adv. Immunol. 44:265 2. Reinherz, E. L. et al. (1980) J. Immunol. 124:1301 3. Fischer, A. et al. (1983) Immunology 48:177 4. Merkenschlanger, M. et al. (1988) Eur. J. Immunol. 18:1653 5. Leukocyte Typing: 3rd Workshop: Code No. 567; 4th Workshop: Code No. N31

Related Products

Product NameProduct CodeSupplier 
Anti-Human CD8 - FITCLEI-C119Leinco Technologies Summary Details
Anti-Human CD8 - PELEI-C120Leinco Technologies Summary Details
Anti-Human CD8 - DyLight® 488LEI-C2060Leinco Technologies Summary Details
Anti-Human CD8 - DyLight® 550LEI-C2061Leinco Technologies Summary Details
Anti-Human CD8 - DyLight® 594LEI-C2062Leinco Technologies Summary Details
Anti-Human CD8 - DyLight® 650LEI-C2064Leinco Technologies Summary Details
Anti-Human CD8 - DyLight® 755LEI-C2066Leinco Technologies Summary Details
Anti-Human CD8 - PerCPLEI-C2068Leinco Technologies Summary Details
Anti-Mouse CD8 (Clone YTS 169) - Purified in vivo PLATINUM™ Functional GradeLEI-C2850Leinco Technologies Summary Details
Anti-Human CD8 - APCLEI-C312Leinco Technologies Summary Details
Anti-Human CD8 - Purified in vivo GOLD™ Functional GradeLEI-C366Leinco Technologies Summary Details